Geode Capital Management
NRXP icon

Geode Capital Management’s NRX Pharmaceuticals NRXP Stock Holding History

Geode Capital Management’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Buy
314,659
+4,547
+1% +$15K ﹤0.01% 3293
2026
Q1 		$661K Buy
310,112
+91,246
+42% +$184K ﹤0.01% 3485
2025
Q4 		$593K Buy
218,866
+33,004
+18% +$88.6K ﹤0.01% 3533
2025
Q3 		$613K Buy
185,862
+13,607
+8% +$39K ﹤0.01% 3538
2025
Q2 		$562K Buy
172,255
+37,598
+28% +$94.2K ﹤0.01% 3518
2025
Q1 		$276K Buy
134,657
+60,406
+81% +$170K ﹤0.01% 3747
2024
Q4 		$163K Sell
74,251
-3,090
-4% -$4.15K ﹤0.01% 3961
2024
Q3 		$131K Buy
77,341
+11,682
+18% +$23.5K ﹤0.01% 4033
2024
Q2 		$160K Buy
65,659
+23,664
+56% +$84.2K ﹤0.01% 3991
2024
Q1 		$198K Buy
41,995
+803
+2% +$3.7K ﹤0.01% 3944
2023
Q4 		$190K Hold
41,192
– – ﹤0.01% 3962
2023
Q3 		$107K Buy
41,192
+3,325
+9% +$11.1K ﹤0.01% 4225
2023
Q2 		$183K Hold
37,867
– – ﹤0.01% 4080
2023
Q1 		$250K Hold
37,867
– – ﹤0.01% 3937
2022
Q4 		$420K Buy
37,867
+5,804
+18% +$58.5K ﹤0.01% 3741
2022
Q3 		$237K Buy
32,063
+1,220
+4% +$8.22K ﹤0.01% 4107
2022
Q2 		$185K Buy
30,843
+1,456
+5% +$19.1K ﹤0.01% 4316
2022
Q1 		$719K Buy
29,387
+8,237
+39% +$268K ﹤0.01% 3764
2021
Q4 		$1.01M Buy
21,150
+16,573
+362% +$1.2M ﹤0.01% 3717
2021
Q3 		$424K Buy
4,577
+1,129
+33% +$147K ﹤0.01% 4107
2021
Q2 		$400K Buy
+3,448
New +$910K ﹤0.01% 4040

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management's NRXP Position: Q2 2026 in Review

Geode Capital Management increased its NRX Pharmaceuticals (NRXP) stake by 1.5% in Q2 2026, buying an estimated $15K and bringing the position to 314,659 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #3293.

Geode Capital Management first reported a position in NRXP in Q2 2021 and has held it in 21 quarters since. 46 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

  • Geode Capital Management held 314,659 shares of NRX Pharmaceuticals worth $1.29M as of Q2 2026.
  • Geode Capital Management bought 4,547 NRX Pharmaceuticals shares in Q2 2026, an estimated $15K.
  • NRX Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3293 holding.
  • Geode Capital Management first reported a position in NRX Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • 46 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.